MARKET

SMMT

SMMT

SUMMIT THERAP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.530
-0.030
-1.92%
After Hours: 1.580 +0.05 +3.27% 17:13 11/14 EST
OPEN
1.540
PREV CLOSE
1.560
HIGH
1.640
LOW
1.530
VOLUME
16.56K
TURNOVER
--
52 WEEK HIGH
2.460
52 WEEK LOW
1.100
MARKET CAP
49.11M
P/E (TTM)
-1.2197
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SMMT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SMMT News

  • Summit Therapeutics Sees Hammer Chart Pattern: Time to Buy?
  • Zacks.6d ago
  • Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
  • GlobeNewswire.11/06 12:00
  • Summit Therapeutics Recognises C. difficile Awareness Month
  • GlobeNewswire.11/04 12:00
  • Top Ranked Momentum Stocks to Buy for October 22nd
  • Zacks.10/22 16:02

More

Industry

Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
-0.27%

Hot Stocks

Name
Price
%Change

About SMMT

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the infectious disease Clostridium difficile infection (CDI). Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid.
More

Webull offers Summit Therapeutics PLC (SMMT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.